Next-generation sequencing and its application in acute myeloid leukemia and myelodysplastic syndrome.
- Author:
Shu-Cheng GU
1
;
Chun-Kang CHANG
Author Information
1. Department of Hematology, Shanghai Jiaotong University, Shanghai, China.
- Publication Type:Journal Article
- MeSH:
Base Sequence;
Genome, Human;
Hematologic Neoplasms;
genetics;
Humans;
Leukemia, Myeloid, Acute;
genetics;
Myelodysplastic Syndromes;
genetics;
Sequence Analysis;
methods
- From:
Journal of Experimental Hematology
2011;19(6):1545-1549
- CountryChina
- Language:Chinese
-
Abstract:
The next-generation sequencing (NGS), as the most practical and reliable method, has replaced the classical Sanger sequencing to help scientists to discover the genetics secrets of human tumor diseases. With the technique development, the whole genome sequencing will be no longer out of reach. Recently, some scientists used the NGS in the research of hematological malignancies and pushed the progress of the whole genome sequencing in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) actively in order to find out the pathogenesis of some hematological malignancies. The NGS and the application of the whole genome sequencing, the exome sequencing, the transcriptome sequencing in AML and MDS are reviewed in this article.
